stockrowACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
- Revenue
- +22.9%
- EPS
- −27.9%
- Free cash flow
- +141.2%
Quarter to September 2026, against a year earlier
Follow ACAD
Alert me
ACADIA Pharmaceuticals Inc. (ACAD) Shares outstanding
ACADIA Pharmaceuticals Inc.'s shares outstanding at the end of fiscal 2025 was $169.9M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $175.5M. Over the past ten years it has ranged from $100.6M (fiscal 2015) to $169.9M (fiscal 2025) — the current reading is the highest in ten years. ACADIA Pharmaceuticals Inc. ranks 62nd of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $169.9M | 2.14% |
| FY2024 | $166.4M | 1.55% |
| FY2023 | $163.8M | 1.32% |
| FY2022 | $161.7M | 0.74% |
| FY2021 | $160.5M | 2.01% |
| FY2020 | $157.3M | 6.88% |
| FY2019 | $147.2M | 16.29% |
| FY2018 | $126.6M | 3.25% |
| FY2017 | $122.6M | 5.82% |
| FY2016 | $115.9M | 15.13% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $175.5M | 1.51% |
| Jun 2026 | $172.9M | 0.08% |
| Mar 2026 | $172.7M | 1.64% |
| Dec 2025 | $169.9M | (0.43%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IOVA Iovance Biotherapeutics, Inc. compare | $450.2M |
| RLAY Relay Therapeutics, Inc. compare | $202.8M |
| ACAD ACADIA Pharmaceuticals Inc. | $175.5M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| TNGX Tango Therapeutics, Inc. compare | $149.9M |
| VKTX Viking Therapeutics, Inc. compare | $118.1M |
| XENE Xenon Pharmaceuticals Inc. compare | $99.6M |
| IRON Disc Medicine, Inc. compare | $38.7M |
| PBLS Parabilis Medicines, Inc. compare | $28.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ACAD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement